Publicaciones en colaboración con investigadores/as de Consiglio Nazionale delle Ricerche (22)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  3. Guidelines for minimal information on cellular senescence experimentation in vivo

    Cell, Vol. 187, Núm. 16, pp. 4150-4175

  4. Integrating bioprinting, cell therapies and drug delivery towards in vivo regeneration of cartilage, bone and osteochondral tissue

    Drug Delivery and Translational Research, Vol. 14, Núm. 4, pp. 858-894

  5. N-Adamantyl-1-alkyl-4-oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as Fluorescent Probes to Detect Microglia Activation through the Imaging of Cannabinoid Receptor Subtype 2 (CB2R)

    Journal of Medicinal Chemistry, Vol. 67, Núm. 13, pp. 11003-11023

  6. Proceedings of the annual meeting of the European Consortium of Lipodystrophies (ECLip), Pisa, Italy, 28–29 September 2023

    Annales d'Endocrinologie

2023

  1. Antiviral Peptides Delivered by Chitosan-Based Nanoparticles to Neutralize SARS-CoV-2 and HCoV-OC43

    Pharmaceutics, Vol. 15, Núm. 6

  2. Biofunctionalization of 3D printed collagen with bevacizumab-loaded microparticles targeting pathological angiogenesis

    Journal of Controlled Release, Vol. 360, pp. 747-758

  3. Development of N-(1-Adamantyl)benzamides as Novel Anti-Inflammatory Multitarget Agents Acting as Dual Modulators of the Cannabinoid CB2 Receptor and Fatty Acid Amide Hydrolase

    Journal of Medicinal Chemistry, Vol. 66, Núm. 1, pp. 235-250

  4. N-adamantyl-anthranil amide derivatives: New selective ligands for the cannabinoid receptor subtype 2 (CB2R)

    European Journal of Medicinal Chemistry, Vol. 248

  5. Novel thienocycloalkylpyridazinones as useful scaffolds for acetylcholinesterase inhibition and serotonin 5-HT6 receptor interaction

    Bioorganic and Medicinal Chemistry, Vol. 84

2022

  1. HuR-targeted agents: An insight into medicinal chemistry, biophysical, computational studies and pharmacological effects on cancer models

    Advanced Drug Delivery Reviews, Vol. 181

2021

  1. Pharmacological inactivation of the prion protein by targeting a folding intermediate

    Communications Biology, Vol. 4, Núm. 1

  2. Synthesis and Biological Evaluation of Dantrolene-Like Hydrazide and Hydrazone Analogues as Multitarget Agents for Neurodegenerative Diseases

    ChemMedChem, Vol. 16, Núm. 18, pp. 2807-2816

2020

  1. European lipodystrophy registry: Background and structure

    Orphanet Journal of Rare Diseases, Vol. 15, Núm. 1

2019

  1. Altered adipocyte differentiation and unbalanced autophagy in type 2 Familial Partial Lipodystrophy: an in vitro and in vivo study of adipose tissue browning

    Experimental and Molecular Medicine, Vol. 51, Núm. 8

2018

  1. Gene therapy approaches in the non-human primate model of Parkinson’s disease

    Journal of Neural Transmission, Vol. 125, Núm. 3, pp. 575-589

  2. Laminopathies

    Nucleus (Austin, Tex.)

2010

  1. Reduced adipogenic gene expression in fibroblasts from a patient with type 2 congenital generalized lipodystrophy

    Diabetic Medicine, Vol. 27, Núm. 10, pp. 1178-1187

2009

  1. Site-dependent differences in both prelamin A and adipogenic genes in subcutaneous adipose tissue of patients with type 2 familial partial lipodystrophy

    Journal of Medical Genetics, Vol. 46, Núm. 1, pp. 40-48